AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23556505 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation with Large Changes (create a weight loss buffer of 5-10 pounds once per year)
Number of subjects: 600
Study 23556505 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control
Number of subjects: 600
Study 21309063 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hypoglycaemic agents (pioglitazone, metformin, glipizide)
Number of subjects: 21
Study 21309063 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy
Number of subjects: 21
Study 19478041 — intervention group
Group type: COMPARATOR
Intervention: Rituximab alone
Number of subjects: 19
Study 19478041 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab + cyclophosphamide
Number of subjects: 19
Study 19478041 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 17761585 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign-born women living in the US for 4 or fewer years
Number of subjects: 662
Study 17761585 — intervention group
Group type: COMPARATOR
Intervention: Native-born women
Number of subjects: 662
Study 17761585 — intervention group
Group type: COMPARATOR
Intervention: White women
Number of subjects: 662
Study 17761585 — intervention group
Group type: EXPERIMENTAL
Intervention: Women speaking both English and Spanish at home
Number of subjects: 662
Study 15239254 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (3 x 200 microg/day for 2 months followed by 20mg octreotide LAR every 4 weeks)
Number of subjects: 58
Study 15239254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40-80 mg)
Number of subjects: 58
Study 15239254 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (80-90 mg/m2 over 24 hours weekly in cycles of 4 weeks)
Number of subjects: 58
Study 15239254 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified in the study)
Number of subjects: 58
Study 12362007 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention program including physical therapy
Number of subjects: 188
Study 12362007 — intervention group
Group type: COMPARATOR
Intervention: Educational program (control)
Number of subjects: 188
Study 9657579 — intervention group
Group type: EXPERIMENTAL
Intervention: ECSC prediction equations
Number of subjects: 12900
Study 9657579 — intervention group
Group type: COMPARATOR
Intervention: Active smokers
Number of subjects: 12900
Study 8020902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg/day for 10 days, first intravenously then orally) plus intravenous bolus of amoxicillin plus clavulanic acid (1 g) before each endoscopy
Number of subjects: 91
Study 8020902 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy only in cases of established or suspected infection
Number of subjects: 91
Study 2614487 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain amino acids (BCAA)
Number of subjects: 32
Study 2614487 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 1069328 — intervention group
Group type: EXPERIMENTAL
Intervention: A group received KR (knowledge of results) to the full second during the first 20 trials and to .01th of a second during the second 20 trials.
Number of subjects: 24
Study 1069328 — intervention group
Group type: COMPARATOR
Intervention: B group received KR to .01th of a second during the first 20 trials and to the full second during the second 20 trials.
Number of subjects: 24
Study 29622506 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (aspirin, statin, and two blood pressure lowering drugs)
Number of subjects: 0
Study 29622506 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27197288 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively decreasing reduced nicotine content (RNC) cigarettes
Number of subjects: 158
Study 27197288 — intervention group
Group type: COMPARATOR
Intervention: Control group smoking their own brand
Number of subjects: 158
Study 24508648 — intervention group
Group type: EXPERIMENTAL
Intervention: N-back working memory paradigm (2-back)
Number of subjects: 51
Study 24508648 — intervention group
Group type: COMPARATOR
Intervention: N-back working memory paradigm (0-back)
Number of subjects: 51
Study 24508648 — intervention group
Group type: COMPARATOR
Intervention: Resting state
Number of subjects: 51
Study 24508648 — intervention group
Group type: COMPARATOR
Intervention: Passive visual stimulation
Number of subjects: 51
Study 22465565 — intervention group
Group type: COMPARATOR
Intervention: Sucrose solution (sweet)
Number of subjects: 0
Study 22465565 — intervention group
Group type: COMPARATOR
Intervention: Menthol vapor
Number of subjects: 0
Study 22465565 — intervention group
Group type: COMPARATOR
Intervention: Sucrose octaacetate solution (bitter)
Number of subjects: 0
Study 20607310 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting (5-Fr, 4-cm-long stent with a single pigtail at the duodenal end)
Number of subjects: 70
Study 20607310 — intervention group
Group type: COMPARATOR
Intervention: No pancreatic duct stenting (no-stent group)
Number of subjects: 70
Study 17668874 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day, 20 mg/day, and 40 mg/day for 4 weeks
Number of subjects: 15
Study 16261108 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous morphine (SC)
Number of subjects: 73
Study 16261108 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural morphine (ED)
Number of subjects: 73
Study 16261108 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DS)
Number of subjects: 73
Study 12105163 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 679
Study 10995135 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope in the activated position
Number of subjects: 10
Study 10995135 — intervention group
Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 10
Study 8826100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 150 micrograms/kg
Number of subjects: 69
Study 8826100 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg with a fatty breakfast for three consecutive days
Number of subjects: 69
Study 8826100 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 69
Study 2291289 — intervention group
Group type: EXPERIMENTAL
Intervention: Poncho-like shirts made of cotton (A)
Number of subjects: 55
Study 2291289 — intervention group
Group type: EXPERIMENTAL
Intervention: Poncho-like shirts made of synthetic fibers (B, C, D)
Number of subjects: 55
Study 2291289 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls wearing poncho-like shirts
Number of subjects: 55
Study 7197116 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein-based diet
Number of subjects: 24
Study 7197116 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein-based diet
Number of subjects: 24
Study 7197116 — intervention group
Group type: COMPARATOR
Intervention: Both diets (animal and soy protein)
Number of subjects: 24
Study 30293184 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Silorane + Silorane System Adhesive
Number of subjects: 70
Study 30293184 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z250 + Clearfil SE Bond
Number of subjects: 70
Study 28746019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse consultation
Number of subjects: 213
Study 25893651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for 10 weeks prior to bariatric surgery
Number of subjects: 80
Study 25893651 — intervention group
Group type: COMPARATOR
Intervention: Nutritional support and education (Control)
Number of subjects: 80
Study 24032741 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-trimester routine ultrasound
Number of subjects: 6780
Study 21724838 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (0.01, 0.02, 0.04, or 0.06 mg protein/kg)
Number of subjects: 30
Study 21724838 — intervention group
Group type: COMPARATOR
Intervention: Daily GH treatment (0.035 mg protein/kg for seven doses)
Number of subjects: 30
Study 21724838 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (0.06 mg protein/kg)
Number of subjects: 30
Study 21724838 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (all doses)
Number of subjects: 30
Study 19190658 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (A/V)
Number of subjects: 572
Study 19190658 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (A)
Number of subjects: 572
Study 17683452 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based Early Intensive Behavioural Interventions (EIBI)
Number of subjects: 44
Study 17683452 — intervention group
Group type: COMPARATOR
Intervention: Autism-specific nursery provision
Number of subjects: 44
Study 14752594 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch urethropexy (BU)
Number of subjects: 73
Study 14752594 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch urethropexy (BU) with concomitant abdominal paravaginal repair (APR)
Number of subjects: 73
Study 14752594 — intervention group
Group type: COMPARATOR
Intervention: Burch urethropexy (BU) only
Number of subjects: 73
Study 11846327 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg daily
Number of subjects: 116
Study 11846327 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen plus medroxyprogesterone acetate (CCEP) 0.625 mg plus 5 mg daily
Number of subjects: 116
Study 9728260 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 41
Study 9728260 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 41
Study 9728260 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 41
Study 9728260 — intervention group
Group type: COMPARATOR
Intervention: Control (0.7 MAC)
Number of subjects: 41
Study 9728260 — intervention group
Group type: COMPARATOR
Intervention: Control (0.7 to 1.3 MAC)
Number of subjects: 41
Study 8042718 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 8042718 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 50
Study 3109661 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkler needle
Number of subjects: 21
Study 3109661 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle
Number of subjects: 21
Study 31609077 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS062D lotion
Number of subjects: 24
Study 31609077 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic cream
Number of subjects: 24
Study 30053279 — intervention group
Group type: COMPARATOR
Intervention: 0 g protein (Group A)
Number of subjects: 28
Study 30053279 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g protein (Group B)
Number of subjects: 28
Study 30053279 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 g protein (Group C)
Number of subjects: 28
Study 30053279 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 g protein (Group D)
Number of subjects: 28
Study 28693622 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Recovery Therapy (SRT) plus optimised treatment as usual (enhanced standard care)
Number of subjects: 270
Study 28693622 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care alone
Number of subjects: 270
Study 25713280 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia
Number of subjects: 0
Study 25713280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental developmental index <70 at 18 months
Number of subjects: 0
Study 25713280 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal IQ
Number of subjects: 0
Study 25713280 — intervention group
Group type: EXPERIMENTAL
Intervention: IQ scores of 70 to 84
Number of subjects: 0
Study 23007142 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 20
Study 23007142 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 20
Study 17272948 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 0
Study 17272948 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy
Number of subjects: 0
Study 14585937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (5.0, 7.5, or 10.0 mg subcutaneously once daily)
Number of subjects: 2213
Study 14585937 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (continuous intravenous infusion)
Number of subjects: 2213
Study 14585937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 2213
Study 14585937 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 2213
Study 10875589 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous antegrade/retrograde reperfusion
Number of subjects: 24
Study 10875589 — intervention group
Group type: COMPARATOR
Intervention: Retrograde reperfusion only
Number of subjects: 24
Study 10875589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 8953998 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC)
Number of subjects: 50
Study 8953998 — intervention group
Group type: COMPARATOR
Intervention: Standard contact (SC)
Number of subjects: 50
Study 1750102 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg base chloroquine once weekly
Number of subjects: 49
Study 1750102 — intervention group
Group type: COMPARATOR
Intervention: 200 mg daily proguanil
Number of subjects: 49
Study 1750102 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg base chloroquine/kg (25 CQ) over three days for treatment of breakthroughs
Number of subjects: 49
Study 7102531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pindolol 5 mg
Number of subjects: 16
Study 7102531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pindolol 10 mg
Number of subjects: 16
Study 7102531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pindolol 15 mg
Number of subjects: 16
Study 7102531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pindolol 20 mg
Number of subjects: 16
Study 7102531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release pindolol 20 mg
Number of subjects: 16
Study 7102531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release pindolol 30 mg
Number of subjects: 16
Study 7102531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pindolol 0.045 mg/kg
Number of subjects: 16
Study 7102531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol 80 mg
Number of subjects: 16
Study 7102531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol 0.3 mg/kg
Number of subjects: 16
Study 28727703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 7 µ/kg
Number of subjects: 44
Study 24750689 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary behavioural modification treatment with exercise
Number of subjects: 21
Study 24750689 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary behavioural modification treatment without exercise
Number of subjects: 21
Study 24750689 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 21
Study 23807255 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment combined with orthognathic surgery
Number of subjects: 28
Study 23807255 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal malocclusion questionnaire
Number of subjects: 28
Study 23807255 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment outcomes satisfaction
Number of subjects: 28
Study 23807255 — intervention group
Group type: EXPERIMENTAL
Intervention: High OHRQoL scores
Number of subjects: 28
Study 23807255 — intervention group
Group type: EXPERIMENTAL
Intervention: OHIP‐G14 scores
Number of subjects: 28
Study 21724794 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention with individualized contacts (two to ten) with nurses
Number of subjects: 361
Study 21724794 — intervention group
Group type: COMPARATOR
Intervention: Control group (less educated patients with only primary education)
Number of subjects: 361
Study 19370737 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg/day
Number of subjects: 25
Study 19370737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 16719602 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic plus hypnosis
Number of subjects: 45
Study 16719602 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic
Number of subjects: 45
Study 16719602 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic plus attention
Number of subjects: 45
Study 15071189 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (100 mg three times per day)
Number of subjects: 22
Study 15071189 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 22
Study 11903914 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. erythromycin 2 mg kg‐1 over 20 min
Number of subjects: 32
Study 11903914 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual isosorbide 10 mg
Number of subjects: 32
Study 11903914 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 32
Study 9269060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (CIM)
Number of subjects: 14
Study 9269060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 14
Study 8330156 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 12
Study 8330156 — intervention group
Group type: COMPARATOR
Intervention: Control (no desmopressin)
Number of subjects: 12
Study 2449904 — intervention group
Group type: EXPERIMENTAL
Intervention: PAF
Number of subjects: 8
Study 2449904 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2
Number of subjects: 8
Study 2449904 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 8
Study 2449904 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 8
Study 28969438 — intervention group
Group type: EXPERIMENTAL
Intervention: 7,000-lux bright white light
Number of subjects: 46
Study 28969438 — intervention group
Group type: COMPARATOR
Intervention: 50-lux dim red placebo light
Number of subjects: 46
Study 28969438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 26302850 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/day of vitamin D3
Number of subjects: 32
Study 26302850 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day of vitamin D3
Number of subjects: 32
Study 26302850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (400 IU and 800 IU)
Number of subjects: 32
Study 24633018 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel Node Biopsy (SNB) plus Wide Local Excision (WLE)
Number of subjects: 5840
Study 24633018 — intervention group
Group type: COMPARATOR
Intervention: Wide Local Excision (WLE) only (Observation group)
Number of subjects: 5840
Study 23966145 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential electrical stimulation (IES)
Number of subjects: 11
Study 23966145 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulus (same protocol without electrical output)
Number of subjects: 11
Study 20174950 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS cholecystectomy
Number of subjects: 40
Study 20174950 — intervention group
Group type: COMPARATOR
Intervention: Classic laparoscopic cholecystectomy
Number of subjects: 40
Study 18586645 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) group - 6 fish oil capsules per day (0.65 g DHA and 0.10 g EPA/day) for 3 months
Number of subjects: 233
Study 18586645 — intervention group
Group type: COMPARATOR
Intervention: Control group - Soybean oil capsules
Number of subjects: 233
Study 18586645 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA group
Number of subjects: 233
Study 16875902 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention pacing therapies (PPTs)
Number of subjects: 546
Study 16875902 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 546
Study 14633951 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFN 0.5 microg/kg
Number of subjects: 60
Study 14633951 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFN 1.0 microg/kg
Number of subjects: 60
Study 14633951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11709865 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (educational intervention)
Number of subjects: 105
Study 11709865 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 105
Study 8784909 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formulas with iron
Number of subjects: 0
Study 8784909 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formulas with low iron
Number of subjects: 0
Study 8784909 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formulas
Number of subjects: 0
Study 8784909 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein hydrolyzate formulas
Number of subjects: 0
Study 1617318 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI without lung shielding (n = 33)
Number of subjects: 64
Study 1617318 — intervention group
Group type: COMPARATOR
Intervention: TBI with lung shielding (n = 31, control group)
Number of subjects: 64
Study 1617318 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI without lung shielding
Number of subjects: 64
Study 1617318 — intervention group
Group type: COMPARATOR
Intervention: TBI with lung shielding (control group)
Number of subjects: 64
Study 6240166 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetracycline (1000 mg daily for 5 days, then 250 mg daily)
Number of subjects: 49
Study 6240166 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracycline (2% alcoholic solution)
Number of subjects: 49
Study 30772130 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Nasotracheal Intubation (FNI) using Ambu aScope Slim
Number of subjects: 20
Study 30772130 — intervention group
Group type: COMPARATOR
Intervention: Blind Nasotracheal Intubation using Parker Endotrol tube
Number of subjects: 20
Study 30772130 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Nasotracheal Intubation (FNI)
Number of subjects: 20
Study 30772130 — intervention group
Group type: COMPARATOR
Intervention: Blind Nasotracheal Intubation
Number of subjects: 20